ZBIO: the cash flow

MyFinsight

For the year ending 2025-12-31, ZBIO had -$209,191K decrease in cash & cash equivalents over the period. -$172,351K in free cash flow.

Cash Flow	2025-12-31
Net loss	-377,737
Acquired in-process research and development	171,672
Depreciation expense	56
Loss on disposal of property and equipment	-107
Net amortization of premiums and accretion of discounts on investments	-1,931
Non-cash interest expense on royalty obligation	7,327
Stock-based compensation expense	26,347
Non-cash lease expense	875
Prepaid expenses and other assets	3,156
Accounts payable	-10,043
Accrued expenses	15,052
Operating lease liabilities	-902
Net cash used in operating activities	-172,333
Purchases of property and equipment	18
Purchases of investments	417,755
Proceeds from sales and maturities of investments	200,887
Product candidate license acquisitions	35,000
Net cash used in investing activities	-251,886
Payment of agent fees and offering costs-Private Placement And At Offering	12,665
Proceeds from royalty obligation	75,000
Proceeds from exercise of stock options	4,096
Proceeds from issuance of common stock under employee stock purchase plan	276
Proceeds from issuance of common stock-Private Placement	120,000
Proceeds from issuance of common stock-At Market Offering	28,573
Net cash provided by financing activities	215,280
Effect of exchange rate changes on cash, cash equivalents and restricted cash	-252
Net (decrease) increase in cash, cash equivalents and restricted cash	-209,191
Cash, cash equivalents and restricted cash at beginning of period	319,832
Cash, cash equivalents and restricted cash at end of period	110,641

Unit: Thousand (K) dollars (except for numbers of shares and EPS).